Cargando…

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochmair, Maximilian J., Fabikan, Hannah, Illini, Oliver, Weinlinger, Christoph, Setinek, Ulrike, Krenbek, Dagmar, Prosch, Helmut, Rauter, Markus, Schumacher, Michael, Wöll, Ewald, Wass, Romana, Brehm, Elmar, Absenger, Gudrun, Bundalo, Tatjana, Errhalt, Peter, Urban, Matthias, Valipour, Arschang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694976/
https://www.ncbi.nlm.nih.gov/pubmed/33171712
http://dx.doi.org/10.3390/ph13110371
_version_ 1783615094174777344
author Hochmair, Maximilian J.
Fabikan, Hannah
Illini, Oliver
Weinlinger, Christoph
Setinek, Ulrike
Krenbek, Dagmar
Prosch, Helmut
Rauter, Markus
Schumacher, Michael
Wöll, Ewald
Wass, Romana
Brehm, Elmar
Absenger, Gudrun
Bundalo, Tatjana
Errhalt, Peter
Urban, Matthias
Valipour, Arschang
author_facet Hochmair, Maximilian J.
Fabikan, Hannah
Illini, Oliver
Weinlinger, Christoph
Setinek, Ulrike
Krenbek, Dagmar
Prosch, Helmut
Rauter, Markus
Schumacher, Michael
Wöll, Ewald
Wass, Romana
Brehm, Elmar
Absenger, Gudrun
Bundalo, Tatjana
Errhalt, Peter
Urban, Matthias
Valipour, Arschang
author_sort Hochmair, Maximilian J.
collection PubMed
description In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, real-world use of lorlatinib in patients with advanced ALK- or ROS1-positive lung cancer. Fifty-one patients registered in a compassionate use program in Austria, who received second- or later-line lorlatinib between January 2016 and May 2020, were included in this retrospective real-world data analysis. Median follow-up was 25.3 months. Median time of lorlatinib treatment was 4.4 months for ALK-positive and 12.2 months for ROS-positive patients. ALK-positive patients showed a response rate of 43.2%, while 85.7% percent of the ROS1-positive patients were considered responders. Median overall survival from lorlatinib initiation was 10.2 and 20.0 months for the ALK- and ROS1-positive groups, respectively. In the ALK-positive group, lorlatinib proved efficacy after both brigatinib and alectinib. Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced ALK- and ROS1-positive lung cancer.
format Online
Article
Text
id pubmed-7694976
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76949762020-11-28 Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis Hochmair, Maximilian J. Fabikan, Hannah Illini, Oliver Weinlinger, Christoph Setinek, Ulrike Krenbek, Dagmar Prosch, Helmut Rauter, Markus Schumacher, Michael Wöll, Ewald Wass, Romana Brehm, Elmar Absenger, Gudrun Bundalo, Tatjana Errhalt, Peter Urban, Matthias Valipour, Arschang Pharmaceuticals (Basel) Article In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, real-world use of lorlatinib in patients with advanced ALK- or ROS1-positive lung cancer. Fifty-one patients registered in a compassionate use program in Austria, who received second- or later-line lorlatinib between January 2016 and May 2020, were included in this retrospective real-world data analysis. Median follow-up was 25.3 months. Median time of lorlatinib treatment was 4.4 months for ALK-positive and 12.2 months for ROS-positive patients. ALK-positive patients showed a response rate of 43.2%, while 85.7% percent of the ROS1-positive patients were considered responders. Median overall survival from lorlatinib initiation was 10.2 and 20.0 months for the ALK- and ROS1-positive groups, respectively. In the ALK-positive group, lorlatinib proved efficacy after both brigatinib and alectinib. Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced ALK- and ROS1-positive lung cancer. MDPI 2020-11-07 /pmc/articles/PMC7694976/ /pubmed/33171712 http://dx.doi.org/10.3390/ph13110371 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hochmair, Maximilian J.
Fabikan, Hannah
Illini, Oliver
Weinlinger, Christoph
Setinek, Ulrike
Krenbek, Dagmar
Prosch, Helmut
Rauter, Markus
Schumacher, Michael
Wöll, Ewald
Wass, Romana
Brehm, Elmar
Absenger, Gudrun
Bundalo, Tatjana
Errhalt, Peter
Urban, Matthias
Valipour, Arschang
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
title Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
title_full Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
title_fullStr Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
title_full_unstemmed Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
title_short Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
title_sort later-line treatment with lorlatinib in alk- and ros1-rearrangement-positive nsclc: a retrospective, multicenter analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694976/
https://www.ncbi.nlm.nih.gov/pubmed/33171712
http://dx.doi.org/10.3390/ph13110371
work_keys_str_mv AT hochmairmaximilianj laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT fabikanhannah laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT illinioliver laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT weinlingerchristoph laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT setinekulrike laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT krenbekdagmar laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT proschhelmut laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT rautermarkus laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT schumachermichael laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT wollewald laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT wassromana laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT brehmelmar laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT absengergudrun laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT bundalotatjana laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT errhaltpeter laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT urbanmatthias laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis
AT valipourarschang laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis